Invesco Ltd. Stoke Therapeutics, Inc. Transaction History

Invesco Ltd.

$600 Billion
Q3 2025

A detailed history of Invesco Ltd. transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 208,075 shares of STOK stock, worth $5.52 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

208,075

Previous 40,207 417.51%

Holding current value

$5.52 Million

Previous $456,000 972.15%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$11.48 - $24.73 $1.93 Million - $4.15 Million	167,868 Added 417.51%	208,075 $4.89 Million
Q2 2025 Aug 13, 2025	BUY	$5.9 - $11.84 $82,741 - $166,044	14,024 Added 53.56%	40,207 $456,000
Q1 2025 May 12, 2025	BUY	$6.65 - $12.74 $93,884 - $179,863	14,118 Added 117.02%	26,183 $174,000
Q4 2024 Feb 13, 2025	BUY	$10.8 - $13.92 $130,302 - $167,944	12,065 New	12,065 $133,000
Q2 2024 Aug 13, 2024	BUY	$11.03 - $17.52 $4.82 Million - $7.66 Million	437,136 New	437,136 $5.91 Million

Q2 2022 Aug 15, 2022	SELL	$10.36 - $23.93 $1.36 Million - $3.15 Million	-131,674 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$17.19 - $26.1 $2.26 Million - $3.44 Million	131,674 New	131,674 $2.77 Million
Q4 2021 Feb 14, 2022	SELL	$18.11 - $30.72 $168,875 - $286,464	-9,325 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$23.65 - $34.44 $31,288 - $45,564	1,323 Added 16.53%	9,325 $237,000
Q2 2021 Aug 17, 2021	BUY	$30.53 - $41.09 $244,301 - $328,802	8,002 New	8,002 $269,000
Q1 2021 May 17, 2021	SELL	$36.08 - $69.81 $913,870 - $1.77 Million	-25,329 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$33.62 - $61.93 $851,560 - $1.57 Million	25,329 New	25,329 $1.57 Million

Others Institutions Holding STOK

# of Institutions

160

Shares Held

60.2M

Call Options Held

563K

Put Options Held

101K

View Full List

About Stoke Therapeutics, Inc.

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $1.05B
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

More about STOK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account